Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver diseaseZoe Boyer‐Díaz, Jordi Gracia‐Sancho, María Andrés‐Rozas et al.|Journal of Hepatology|2020Cited by 163
Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as NutraceuticalZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Jaime Bosch et al.|Nutrients|2020Cited by 26
A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver DiseaseZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Jaime Bosch et al.|Nutrients|2019Cited by 22
Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal HypertensionChangpeng Zhu, Wei‐Fen Xie, Weihua Dong et al.|Gastroenterology|2024Cited by 12
Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertensionPeio Aristu-Zabalza, Jordi Gracia‐Sancho, María Andrés‐Rozas et al.|Biology of Sex Differences|2025Cited by 8